Firazyr (Icatibant) Copay Assistance

This program provides assistance for Firazyr (icatibant) medication costs through manufacturer copay cards, patient assistance programs, and foundation grants, potentially reducing patient costs to $0. It is available to U.S. residents with a valid Firazyr prescription for hereditary angioedema (HAE), who have commercial insurance, Medicare, Medicaid, or are uninsured. Eligibility often depends on insurance type and financial circumstances, with income-based requirements for some programs.

Eligibility

To be eligible, patients must have a valid Firazyr prescription for hereditary angioedema and maintain U.S. residency. Qualification for specific financial assistance depends on insurance type and household income, which is typically capped between 400% and 500% of the federal poverty level.